Clínic Barcelona

Oxaliplatin Promotes the Survival of Drug-Resistant Colon Tumor Cells

Oxaliplatin is a drug that is widely used to treat colon cancer, but its efficacy is limited by the development of resistance to chemotherapy of the tumor cells. The chemoresistant cells undergo molecular changes that protect them from the cell death induced by the drugs, thus re-establishing the processes of tumor progression. An article published in PLoS One analyzes the role of the metalloproteinase, MMP7, in the resistance mechanisms of these cells and its effect on the Fas receptor involved in promoting cell death by apoptosis. This study was directed by Dr. Vanessa Almendro of the department of medical oncology at Hospital Clínic-IDIBAPS and by Dr. Pere Gascón, and involved the collaboration of Dr. Elisabet Ametller, among others. The results show that, in colon cancer cell lines, MMP7 is directly related to the acquisition of resistance to oxaliplatin and its inhibition re-establishes sensitivity to the drug due to an increase in the Fas receptor. Furthermore, the authors observed that, surprisingly, the Fas receptor undergoes changes in functionality in cells resistant to oxaliplatin, leading it to induce survival signals instead of apoptotic signals.